Given the expanding use of SGLT2i in HF and the lack of HF-specific lipid-focused trials, this narrative review synthesizes current evidence on quantitative lipid changes, emerging particle-level alterations, and mechanistic pathways linking SGLT2 inhibition to lipid metabolism in HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.